| 1 |
33547076 | Targeting oncoproteins with a positive selection assay for protein degraders. | 2021 Feb |
1 |
| 2 |
34530760 | Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial. | 2021 Sep 16 |
1 |
| 3 |
32414180 | Molecular Mechanisms of the Teratogenic Effects of Thalidomide. | 2020 May 13 |
1 |
| 4 |
32929090 | Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide. | 2020 Sep 14 |
1 |
| 5 |
30683719 | Peptidic degron for IMiD-induced degradation of heterologous proteins. | 2019 Feb 12 |
1 |
| 6 |
31157769 | Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs. | 2019 May 15 |
2 |
| 7 |
30064974 | Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. | 2018 Oct 4 |
1 |
| 8 |
30118587 | Homo-PROTACs for the Chemical Knockdown of Cereblon. | 2018 Sep 21 |
2 |
| 9 |
30288348 | The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. | 2018 |
1 |
| 10 |
30385546 | Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. | 2018 Nov 2 |
1 |
| 11 |
24292623 | The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. | 2014 Jan 17 |
1 |